Literature DB >> 11714087

Signal transduction in cardiac hypertrophy--dissecting compensatory versus pathological pathways utilizing a transgenic approach.

Y Wang1.   

Abstract

Targeted and regulated genetic manipulation, physiological intervention to introduce biomechanical stress and injury, sophisticated measurement of cardiac function in transgenic heart at whole organ and cellular level, and the molecular/biochemical/genomic analysis of signaling pathways in cardiomyocytes represent the most significant advances in recent years in this field. Such progress has helped make inroads into understanding the molecular mechanism of cardiac hypertrophy and heart failure. Delineating intracellular signaling pathways involved in the different aspects of cardiac hypertrophy and remodeling will have significant implications in drug development for heart failure.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11714087     DOI: 10.1016/s1471-4892(01)00029-7

Source DB:  PubMed          Journal:  Curr Opin Pharmacol        ISSN: 1471-4892            Impact factor:   5.547


  8 in total

1.  Cardiac hypertrophy and oxidative stress: a leap of faith or stark reality?

Authors:  D Lang
Journal:  Heart       Date:  2002-04       Impact factor: 5.994

2.  Phosphoinositide kinases play key roles in norepinephrine- and angiotensin II-induced increase in phosphatidylinositol 4,5-bisphosphate and modulation of cardiac function.

Authors:  Jia-Xi Xu; Man Si; Hui-Ran Zhang; Xing-Juan Chen; Xi-Dong Zhang; Chuan Wang; Xiao-Na Du; Hai-Lin Zhang
Journal:  J Biol Chem       Date:  2014-01-21       Impact factor: 5.157

3.  Overexpression of mitogen-activated protein kinase kinase 6 in the heart improves functional recovery from ischemia in vitro and protects against myocardial infarction in vivo.

Authors:  Joshua J Martindale; Jason A Wall; Diana M Martinez-Longoria; Prafulla Aryal; Howard A Rockman; Yiru Guo; Roberto Bolli; Christopher C Glembotski
Journal:  J Biol Chem       Date:  2004-10-18       Impact factor: 5.157

4.  Regression from pathological hypertrophy in mice is sexually dimorphic and stimulus specific.

Authors:  Deanna L Muehleman; Claudia Crocini; Alison R Swearingen; Christopher D Ozeroff; Leslie A Leinwand
Journal:  Am J Physiol Heart Circ Physiol       Date:  2022-03-18       Impact factor: 4.733

5.  Simvastatin attenuates hypertrophic responses induced by cardiotrophin-1 via JAK-STAT pathway in cultured cardiomyocytes.

Authors:  LiJun Wu; LianYou Zhao; QiangSun Zheng; FuJun Shang; XianMei Wang; LiFeng Wang; Bing Lang
Journal:  Mol Cell Biochem       Date:  2006-03-14       Impact factor: 3.396

6.  Role of mitogen-activated protein kinase in cardiac hypertrophy and heart failure.

Authors:  Weihua Zhang; Vijayan Elimban; Mohinder S Nijjar; Suresh K Gupta; Naranjan S Dhalla
Journal:  Exp Clin Cardiol       Date:  2003

7.  Improvement in cardiac function of diabetic rats by bosentan is not associated with changes in the activation of PKC isoforms.

Authors:  Jihong Jiang; Violet Yuen; Hong Xiang; John H McNeill
Journal:  Mol Cell Biochem       Date:  2006-01       Impact factor: 3.842

8.  Lycopene Inhibits Urotensin-II-Induced Cardiomyocyte Hypertrophy in Neonatal Rat Cardiomyocytes.

Authors:  Hung-Hsing Chao; Li-Chin Sung; Cheng-Hsien Chen; Ju-Chi Liu; Jin-Jer Chen; Tzu-Hurng Cheng
Journal:  Evid Based Complement Alternat Med       Date:  2014-05-25       Impact factor: 2.629

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.